Internal and Emergency Medicine

, Volume 5, Supplement 1, pp 21–25 | Cite as

Infectious complications in neutropenic cancer patients

Symposium: Managing of Complications in Patients with Cancer

Abstract

Cancer patients are at risk of infectious complications due to neutropenia following chemotherapy or early post-HSCT (Hemato Stem Cell Transplantation). The first episode of fever during recent onset neutropenia is caused mostly by bacteria, while subsequent episodes are mainly fungal in nature. Proper management of infectious complications in neutropenic cancer patients requires classification into the appropriate risk category and knowledge of the local epidemiology of infections, of the causative organisms and their resistance phenotype.

Keywords

Cancer Neutropenia Infectious complications 

Notes

Conflict of interest

None.

References

  1. 1.
    Pizzo PA (1999) Fever in immunocompromised patients. N Engl J Med 341:893–900CrossRefPubMedGoogle Scholar
  2. 2.
    Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P et al (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353(10):988–998CrossRefPubMedGoogle Scholar
  3. 3.
    Bucaneve G, Micozzi A, Menicheti F, Martino P, Dionisi MS, Martinelli G et al (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353(10):977–987CrossRefPubMedGoogle Scholar
  4. 4.
    Gafter-Gvili A, Fraser A, Paul M, Leibovici L (2005) Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142:979–995PubMedGoogle Scholar
  5. 5.
    Walsh T et al (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 340:764–771CrossRefPubMedGoogle Scholar
  6. 6.
    Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E et al (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41(9):1242–1250Google Scholar
  7. 7.
    Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F et al (2009) Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 48(8):1042–1051Google Scholar
  8. 8.
    Cornely OA, Bohme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M et al (2009) Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Hematology and Oncology. Haematologica 94(1):113–122Google Scholar

Copyright information

© SIMI 2010

Authors and Affiliations

  1. 1.Azienda Ospedaliera-Universitaria PisanaPisaItaly

Personalised recommendations